Download PDF
Onkologische Welt 2012; 03(05): 241-245
DOI: 10.1055/s-0038-1630258
Uro-Onkologie
Schattauer GmbH

GnRH-Agonisten in der Therapie des hormonsensitiven Prostatakarzinoms

Neue Erkenntnisse zum Routineeinsatz eines altbekannten StandardsGnRH-agonists in the treatment of hormone-sensitive prostate cancerLearning more on the routine use of a well-known treatment standard
J. Schröder
1   Urologische Praxis Dr. Schröder Berlin
,
J. Scheerer
2   AstraZeneca GmbH Wedel
,
E. Altwein
3   Chirurgische Klinik München-Bogenhausen GmbH, Abteilung Urologie
› Author Affiliations
Further Information

Publication History

Publication Date:
31 January 2018 (online)

    Permissions and Reprints

Zusammenfassung

Einleitung: GnRH-Analoga stellen den Therapiestandard für Patienten mit einem hormonsensitiven fortgeschrittenen Prostatakarzinom dar. Kombi-Injektionsbestecke für subkutan zu applizierende Depot-Implementate wie das Zoladex Safe System® (AstraZeneca) erleichtern die Applikation bei bestmöglichem Schutz des verabreichenden medizinischen Personals.

Methoden: Anwendungserfahrungen bezüglich der erreichten Therapiequalität und -sicherheit wurden im Rahmen eines Qualitätssicherungsprojekts gesammelt, bei dem die Langzeitverabreichung eines 10,8 mg Goserelin 3-Monatsimplantats über einen Zeitraum von 18 Monaten bei mehr als 2000 Patienten dokumentiert und mittels epidemiologischer Methoden ausgewertet wurde.

Ergebnisse: Die sehr gute Verträglichkeit und Wirksamkeit der GnRH-Analoga über das volle Indikationsspektrum beim hormonsensitiven Prostatakarzinom bestätigte sich in dieser Anwendungsbeobachtung. über den gesamten Beobachtungszeitraum lagen die fachliche Beurteilung der Therapiewirksamkeit und Verträglichkeit konstant bei mehr als 93% bzw. 98%. Bei mehr als 10000 Verabreichungen wurde kein einziger Fall einer Stechnadel-induzierten Verletzung des Fachpersonals berichtet. Schlussfolgerungen: Diese Ergebnisse bestätigen den Stellenwert der GnRH-Blockade als gut verträglicher, effektiver und von ärzten wie Patienten geschätzten Therapieoption beim hormonsensitiven Prostatakarzinom.

Summary

Introduction: GnRH analoga represent the acknowledged therapy standard in patients with prostate cancer suited for antihormonal treatment. Ready-to-use injection systems optimise the application for the patient in line with the best-possible protection of the medical personal.

Methods: The use and acceptance of the goserelin application Zoladex 10.8 Safe System™ (AstraZeneca) was studied in more than 2000 patients treated for an interval of 18 months with the 3-months depot. Safety, tolerability and quality of life were assessed at three monthly intervals.

Results: The non-interventional study, using standard epidemiological methods for data analysis, demonstrated a high degree of user satisfaction in terms of the therapeutic efficacy and tolerability (93% and 98%, respectively) over the whole observation period. After 18 months of treatment, the median PSA was lowered from baseline in at least 95% of patients across all strata. More than 10,000 applications of the Safe system were documented without any case of a needle-stick injury of the medical personnel. Conclusion: These results confirm the relevance of the GnRH ablation therapy as an efficient, safe and highly estimated therapeutic option in the treatment of hormone sensitive prostate cancer.

Schlüsselwörter

Prostatakarzinom, - GnRH-Analoga - Goserelin, - Zoladex Safe System®

Keywords

Prostatic neoplasms - GnRH agonists - gosereline - Zoladex Safe System®
 

  • Literatur

  • 1 Scher HI, Heller G.. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology 2000; 55: 323-327.
    CrossrefPubMedGoogle Scholar
  • 2 Labrie F, Bélanger A, Luu-The V. et al. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocrine Reviews 2005; 26: 361-379.
    CrossrefPubMedGoogle Scholar
  • 3 DKG.. Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der ver schiedenen Stadien des Prostatakarzinoms, Version 1.03, März. 2011 http://www.krebsgesellschaft.de/download/s3-leitlinie-prostatakarzinom.pdf (Aufgerufen am 7 Jul 2011).
    PubMedGoogle Scholar
  • 4 Heidenreich A, Bellmunt J, Bolla M. et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71.
    CrossrefPubMedGoogle Scholar
  • 5 Mottet N, Bellmunt J, Bolla M. et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59: 572-583.
    CrossrefPubMedGoogle Scholar
  • 6 Kretzschmar A.. Fortschritte in der Therapie des Prostatakarzinoms. Onk Welt 2011; 2: 43-44.
    Google Scholar
  • 7 Loblaw DA, Virgo KS, Nam R. et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25: 1596-1605.
    CrossrefPubMedGoogle Scholar
  • 8 Evans CP, Fleshner N, Fitzpatrick JM. et al. An evidence-based approach to understanding the pharmacological class effect in the management of prostatic diseases. BJU International 2005; 95: 743-749.
    CrossrefPubMedGoogle Scholar
  • 9 Seidenfeld J, Samson DJ, Hasselblad V. et al. Singletherapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000; 132: 566-577.
    CrossrefPubMedGoogle Scholar
  • 10 Kaisary AV, Tyrrell CJ, Peeling WB. et al. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991; 67: 502-508.
    CrossrefPubMedGoogle Scholar
  • 11 Waymont B, Lynch TH, Dunn JA. et al. Phase III randomised study of Zoladex versus stilboestrol in the treatment of advanced prostate cancer. Br J Urol 1992; 69: 614-620.
    CrossrefPubMedGoogle Scholar
  • 12 Vogelzang NJ, Chodak GW, Soloway MS. et al. Go- serelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomised trial. Urology 1995; 46: 220-226.
    CrossrefPubMedGoogle Scholar
  • 13 Messing EM, Manola J, Sarosdy M. et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781-1788.
    CrossrefPubMedGoogle Scholar
  • 14 Bolla M, Collette L, Blank L. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-108.
    CrossrefPubMedGoogle Scholar
  • 15 Pilepich MV, Winter K, Lawton CA. et al. Androgen suppression adjuvant to definitive radiotherapy in carcinomas of the prostate - long term results of Phase III RTOG 85-31. Int J Rad Oncol Biol Phys 2005; 61: 1285-1290.
    CrossrefPubMedGoogle Scholar
  • 16 Pilepich MV, Winter K, John MJ. et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-1252.
    CrossrefPubMedGoogle Scholar
  • 17 Shipley WU, Lu JD, Pilepich MV. et al. Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy. A secondary analysis of the randomized protocol RTOG 86-10. Int J Radiat Oncol Biol Phys 2002; 54: 1302-1310.
    CrossrefPubMedGoogle Scholar
  • 18 Altwein J, Mohandessi B.. Prostata- und Samenblasentumoren. In: Jocham D, Miller K, Hrsg. Praxis der Urologie, Vol. 2. Stuttgart: Thieme-Verlag; 2003: 174ff.
    Google Scholar
  • 19 Samdal F, Vada K, Lundmo PI. et al. Orchidectomy or LHRH-analogue?. Scand J Urol Nephrol 1991; 25: 197-199.
    CrossrefPubMedGoogle Scholar
  • 20 Cassileth BR, Soloway MS, Vogelzang NJ. et al. Patients’ choice of treatment in stage D prostate cancer. Urology 1989; 33: 57-62.
    PubMedGoogle Scholar
  • 21 Cassileth BR, Soloway MS, Vogelzang NJ. et al. Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group. Qual Life Res 1992; 1: 323-329.
    CrossrefPubMedGoogle Scholar